Experimental PSP drug shows promise in early trial
NCT ID NCT05819658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a higher dose, or a placebo for 6 months. The goal was to see if the drug could slow down the worsening of symptoms like balance and eye movement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyung Hee University Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
-
Seoul National University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Wearable sensors aim to catch neurodegenerative decline in real time
- Experimental antibody aims to tame rare brain disorder
- Scientists decode gait signatures to spot brain diseases
- Scientists hunt for clues to diagnose Parkinson's earlier